Complete Humira Biosimilar List
Humira (adalimumab) was the world’s top-selling drug for over a decade, with U.S. sales peaking at $21.2 billion in 2022. The expiration of AbbVie’s patent protections opened the door for biosimilar competition, and the Humira biosimilar list has grown rapidly since the first U.S. launch in January 2023. As of 2026, the FDA has approved more than ten adalimumab biosimilars, and several are actively competing for market share in pharmacies and health plan formularies.
This Humira biosimilar list provides a comprehensive reference for every FDA-approved adalimumab biosimilar, including approval dates, interchangeable status, manufacturer details, and estimated pricing. Whether you are a patient evaluating a switch, a caregiver researching options, or simply tracking the evolving biosimilar landscape, this guide has the information you need.
Understanding the List: Key Terms
Before reviewing the individual products, understanding a few key terms will help you compare them effectively.
Biosimilar: A biological product highly similar to the reference biologic (Humira) with no clinically meaningful differences in safety, purity, or potency. All products on this list meet this standard.
Interchangeable: A higher designation indicating the biosimilar can be substituted at the pharmacy level without prescriber intervention, similar to how generic drugs are substituted. Not all biosimilars on this list have earned interchangeable status, though several have.
Citrate-free: A formulation that removes citrate, a buffering agent that can cause stinging during injection. Many patients prefer citrate-free versions for improved injection comfort. Humira’s current pen formulation is citrate-free, and most biosimilar manufacturers offer citrate-free options.
WAC (Wholesale Acquisition Cost): The manufacturer’s list price to wholesalers. This is not what patients pay at the pharmacy, but it serves as a benchmark for comparing relative pricing between products.
FDA-Approved Adalimumab Biosimilars
The following products make up the current Humira biosimilar list. They are presented in order of FDA approval date.
1. Amjevita (adalimumab-atto) — Amgen
- FDA approval: September 2016
- U.S. launch: January 2023
- Interchangeable: Yes (granted 2023)
- Citrate-free: Yes
- Pricing: Available at two WAC tiers — approximately 5% and 55% below Humira’s list price
- Notes: First Humira biosimilar to launch in the U.S. Amgen offers a copay assistance program for commercially insured patients.
2. Cyltezo (adalimumab-adbm) — Boehringer Ingelheim
- FDA approval: August 2017
- U.S. launch: July 2023
- Interchangeable: Yes (first adalimumab biosimilar to receive this designation, October 2021)
- Citrate-free: Yes
- Pricing: Discounts of 5% to 80% below Humira WAC depending on payer contract
- Notes: Boehringer Ingelheim positions Cyltezo with flexible pricing to attract plan formulary placement.
3. Hyrimoz (adalimumab-adaz) — Sandoz
- FDA approval: October 2018
- U.S. launch: July 2023
- Interchangeable: Yes (granted 2024)
- Citrate-free: Yes (citrate-free version available)
- Pricing: Discounts of up to 81% below Humira WAC for certain payer contracts
- Notes: Sandoz is one of the world’s largest biosimilar companies. Hyrimoz has extensive post-market safety data from European use since 2018.
4. Hadlima (adalimumab-bwwd) — Samsung Bioepis / Organon
- FDA approval: July 2019
- U.S. launch: July 2023
- Interchangeable: Yes (granted 2023)
- Citrate-free: Yes (available in both formulations)
- Pricing: WAC set at approximately 5% to 10% below Humira for the standard version; citrate-free at similar discount
- Notes: Samsung Bioepis has a growing portfolio of biosimilars across multiple therapeutic areas.
5. Abrilada (adalimumab-afzb) — Pfizer
- FDA approval: November 2019
- U.S. launch: 2023
- Interchangeable: No (biosimilar only as of 2026)
- Citrate-free: Yes
- Pricing: Competitively discounted below Humira WAC
- Notes: Backed by Pfizer’s extensive distribution network. Pfizer offers patient support programs comparable to AbbVie’s Humira Complete.
6. Hulio (adalimumab-fkjp) — Mylan / Viatris
- FDA approval: July 2020
- U.S. launch: 2023
- Interchangeable: No
- Citrate-free: Standard formulation
- Pricing: Positioned at a moderate discount to Humira
- Notes: Viatris focuses on payer contracts and formulary access.
7. Yusimry (adalimumab-aqvh) — Coherus BioSciences
- FDA approval: December 2021
- U.S. launch: 2023
- Interchangeable: No
- Citrate-free: Yes
- Pricing: Up to 85% below Humira WAC in some payer contracts, among the most aggressively priced options
- Notes: Coherus has positioned Yusimry as a value leader to gain formulary access on cost-sensitive plans.
8. Idacio (adalimumab-aacf) — Fresenius Kabi
- FDA approval: December 2022
- U.S. launch: 2023-2024
- Interchangeable: No
- Citrate-free: Yes
- Pricing: Competitive discount below Humira WAC
- Notes: Fresenius Kabi has extensive European experience with Idacio, which has been marketed in the EU since 2019.
9. Simlandi (adalimumab-ryvk) — Teva
- FDA approval: March 2024
- U.S. launch: Second half of 2024
- Interchangeable: Yes
- Citrate-free: Yes
- Pricing: Competitive; Teva targets broad formulary access
- Notes: One of the newer entrants with interchangeable status. Teva is the world’s largest generic pharmaceutical company.
How to Read Your Insurance Formulary
Having a long Humira biosimilar list does not help if you do not know which product your plan covers. Here is how to find out.
Check your plan’s formulary: Your insurance company publishes a formulary (drug list) on its website or through your member portal. Search for “adalimumab” to see which products are covered and at what tier.
Look for preferred products: Plans often designate one or two biosimilars as “preferred,” placing them on a lower copay tier. Using the preferred product saves you the most money. Some plans have removed brand-name Humira from their formulary entirely, making a biosimilar the only covered option.
Ask about prior authorization: Some plans require prior authorization before covering any adalimumab product, whether brand or biosimilar. Your prescriber’s office typically handles this process.
Pricing Comparison
Direct price comparisons are difficult because net prices (after rebates and discounts) differ from list prices. However, here is a general framework based on WAC data:
- Humira (brand): WAC approximately $6,900 per month
- Biosimilars at modest discount (5-10%): $6,200 to $6,550 per month WAC
- Biosimilars at deep discount (50-85%): $1,000 to $3,450 per month WAC
The wide pricing range reflects different manufacturer strategies. Some biosimilar makers price close to Humira to capture rebate-driven formulary placement, while others price aggressively low to win market share. Your actual cost depends on your insurance plan’s negotiated rate, your copay or coinsurance, and whether you use a manufacturer savings card.
For uninsured patients, the deeply discounted biosimilars offer the most direct savings. Check manufacturer websites for patient assistance programs that may further reduce or eliminate costs.
Conditions Treated by Humira Biosimilars
All FDA-approved Humira biosimilars are approved for the same indications as Humira, which include:
- Rheumatoid arthritis
- Juvenile idiopathic arthritis (ages 2 and older)
- Psoriatic arthritis
- Ankylosing spondylitis
- Crohn’s disease (adults and pediatric patients ages 6 and older)
- Ulcerative colitis
- Plaque psoriasis
- Hidradenitis suppurativa
- Uveitis
Some biosimilars are approved for all of these indications through a regulatory process called “extrapolation,” which allows the FDA to extend approval to conditions not directly studied in the biosimilar’s clinical trial, based on the totality of evidence.
Frequently Asked Questions
Which Humira biosimilar is the cheapest?
Based on WAC, Yusimry (Coherus BioSciences) and certain pricing tiers of Hyrimoz (Sandoz) and Cyltezo (Boehringer Ingelheim) offer the deepest discounts, up to 80-85% below Humira’s list price. However, your actual cost depends on your insurance plan’s formulary and negotiated rates. For more on how biosimilars save you money, see our companion guide.
Are all Humira biosimilars interchangeable?
No. As of 2026, Amjevita, Cyltezo, Hadlima, Hyrimoz, and Simlandi have earned interchangeable status. Others are approved as biosimilars but not interchangeable, meaning a pharmacist cannot substitute them without a new prescription from your doctor.
Can I switch between different Humira biosimilars?
Clinically, switching between adalimumab products (including between biosimilars) has not shown increased risk. However, your insurance plan may prefer a specific product. Switching should always be discussed with your doctor and coordinated with your pharmacy and insurer.
Do Humira biosimilars have the same side effects?
Yes. The FDA requires biosimilars to have no clinically meaningful differences in safety compared to the reference product. The side effect profile for all adalimumab biosimilars mirrors that of Humira, including risks of serious infection and malignancy that apply to all TNF inhibitors.
Will more Humira biosimilars be approved?
Additional adalimumab biosimilars are in development by other manufacturers. The FDA continues to review applications, and the competitive landscape is expected to intensify, which should drive prices lower over time.
Choose the Best Option for You
The growing Humira biosimilar list gives patients, prescribers, and payers more choices than ever for treating autoimmune conditions with adalimumab. Review your insurance formulary to identify which product is preferred, compare manufacturer support programs, and talk to your doctor about switching if cost is a concern. For strategies beyond biosimilars, including discount cards, Medicare Extra Help, and patient assistance programs, visit our healthcare costs guide.